News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Congratulations to our SUS Leadership scholarship recipient, Mediget Teshome – Society of Surgical Oncology
Photo from Society of Surgical Oncology/Twitter
Jul 30, 2023, 17:49

Congratulations to our SUS Leadership scholarship recipient, Mediget Teshome – Society of Surgical Oncology

Congratulations to our SUS Leadership scholarship recipient, Mediget Teshome, MD. The SUS program is designed for aspiring surgical leaders to advance their careers in academic medicine amidst an ever-changing landscape. We can’t wait to see all you do with the skills from this program!

Source: Society of Surgical Oncology/Twitter

cancer career leadership Mediget Teshome OncoDaily Oncology Society of Surgical Oncology surgery SUS leadership
Special Coverage
Blog
Aug 5, 2025, 16:13
Al-Ola Abdallah: Daniel Carrizosa Discussed Bispecific T-cell Engagers in SCLC at National ICE-T Conference
Science
Aug 5, 2025, 16:07
Hagop Kantarjian: Discussing the Biology of Acute Lymphocytic Leukaemia
Blog
Aug 5, 2025, 16:04
Loizos G. Loizou: ELPIDA Foundation for Children with Cancer and Leukaemia
Blog
Aug 5, 2025, 15:57
Fabio Ynoe de Moraes: Radiotherapy Can "Heat Up" Cold Lung Tumors and Boost Immunotherapy Responses
Blog
Aug 5, 2025, 15:32
Sumanta Pal: Our Terrific Surgeons are Blazing New Trails for Challenging to Treat Diseases
Opinion
Aug 5, 2025, 15:01
Timothy Winschel: Excited to Share Our Recent Paper Published in Supportive Care in Cancer
Career
Aug 5, 2025, 14:16
Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology
Blog
Aug 5, 2025, 13:23
Can Exercise Change Cancer Care?
Immune Oncology
Aug 5, 2025, 13:09
FDA Fast Track for CLD-201: Stem Cell–Based Oncolytic Virus for Soft Tissue Sarcoma
Insight
Aug 5, 2025, 12:52
Chris Boshoff: Pfizer’s Updates from the Second Quarter
Blog
Aug 5, 2025, 12:52
Davit Zohrabyan: Thanks to The Max Foundation for Giving Patients a Chance to Cancer Treatment
Insight
Aug 5, 2025, 12:39
Lorlatinib as First Treatment for ALK+ Lung Cancer - ALK Positive Inc.